<DOC>
	<DOCNO>NCT01877889</DOCNO>
	<brief_summary>The purpose study compare pharmacodynamics ( ie , drug affect body ) canagliflozin pharmacodynamics dapagliflozin .</brief_summary>
	<brief_title>A Study Compare Pharmacodynamics Canagliflozin Dapagliflozin Healthy Volunteers</brief_title>
	<detailed_description>The study conduct 2-part study . Part 1 open-label pilot study ( investigator participant know identity assign treatment ) 6 healthy volunteer give 300 mg canagliflozin daily 4 consecutive day . The total study duration volunteer Part 1 approximately 35 day ( include screen phase , open-label treatment phase , follow-up phase ) . Part 2 double-blind ( neither investigator volunteer know identity assign treatment ) , randomize ( treatment assign chance ) , 2-period crossover study ( volunteer receive 2 treatment different order ) two-stage sequential group design . Approximately 34 healthy volunteer participate first stage . After participant first stage complete Part 2 , result analyze , base first stage outcome study either terminate proceed second stage , conduct use study method first stage . Potentially , 30 volunteer participate second stage . A total number participant Part 2 64 . Volunteers assign Treatment Sequence 1 receive 10 mg dapagliflozin daily 4 consecutive day ( Period 1 ) , 12- 14-day washout period ( medication ) , 300 mg canagliflozin daily 4 day ( Period 2 ) . Volunteers assign Treatment Sequence 2 receive 300 mg canagliflozin daily 4 day ( Period 1 ) , 12- 14-day washout period , 10 mg dapagliflozin daily 4 consecutive day ( Period 2 ) . The total study duration volunteer Part 2 approximately 65 day ( include screen phase , baseline phase , double-blind treatment phase , washout period , follow-up phase ) . Volunteers participate Part 1 Part 2 study , part . Canagliflozin dapagliflozin use treatment type 2 diabetes mellitus .</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Volunteers must body mass index ( BMI = weight kg/height m2 ) 20 27 kg/m2 ( inclusive ) , body weight &gt; = 50 kg Screening Volunteers must systolic blood pressure 90 140 mmHg , inclusive , diastolic blood pressure high 90 mmHg ( base upon average 3 blood pressure reading Screening ) Volunteers must nonsmoker Major surgery ( eg , require general anesthesia ) within 12 week Screening , plan participation study , within 2 week last dose study drug administration , volunteer fully recover surgery participation study ; volunteer plan surgical procedure conduct local anesthesia may participate History hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antiHCV ) positive , clinically active liver disease , test positive HBsAg antiHCV Screening History human immunodeficiency virus ( HIV ) antibody positive , test positive HIV Screening History , currently active illness , consider clinically significant Investigator illness Investigator considers exclude volunteer study could interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>INVOKANA</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>FORXIGA</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>